Zai Lab to present Phase 1/1b healthy-volunteer data for atopic disease antibody ZL-1503 at ACAAI 2026
ZLAB•Zai Lab plans to present initial Phase 1/1b healthy-volunteer data for its atopic disease antibody ZL-1503 at the ACAAI meeting on Nov. 13, 2026.
1. Data presentation planned
Zai Lab said its initial clinical data for ZL-1503, a bispecific antibody for atopic diseases, will be presented at the ACAAI 2026 meeting on Nov. 13. The update is expected to cover the drug’s behavior in the body, early biomarker effects, and initial safety and immunogenicity observations.
2. Program focus
Zai Lab described ZL-1503 as a potentially longer-acting approach aimed at reducing itch and inflammation in conditions driven by IL-13 and IL-31.
